A client presents in the emergency department with joint pain. Which condition would be least likely to cause this symptom?

Choice A reason: Lithium toxicity is a concern but not inevitable. It occurs with levels above 1.5 mEq/L, often due to dehydration or drug interactions, common in trauma settings. However, routine monitoring of levels is a more immediate nursing priority than assuming toxicity, as early detection prevents severe outcomes like seizures or renal damage.

Choice B reason: Lithium is primarily excreted by the kidneys, not metabolized by the liver. Liver function tests are not indicated for lithium monitoring, as it does not undergo hepatic metabolism. This statement is inaccurate, as renal function tests are critical to assess lithium clearance and prevent toxicity in trauma patients.

Choice C reason: Stress does not directly increase lithium requirements. Trauma-related dehydration or renal impairment can elevate lithium levels, risking toxicity, but this is due to reduced clearance, not increased need. This statement is inaccurate, as dosing adjustments should be based on serum levels, not stress alone.

Choice D reason: Lithium has a narrow therapeutic range (0.6-1.2 mEq/L), and trauma-related factors like dehydration or medications can alter levels, risking toxicity or subtherapeutic effects. Regular serum level monitoring is critical, especially in acute settings, to ensure safety and efficacy, making this statement accurate and a priority nursing concern.

Choice A reason: Phenazopyridine is a urinary analgesic that relieves pain, burning, and irritation in the urinary tract by exerting a topical anesthetic effect on the uroepithelium. It is commonly used for symptomatic relief in UTIs, making this statement accurate, as it directly addresses its therapeutic role in managing urinary discomfort.

Choice B reason: Phenazopyridine is used short-term (typically 2 days) for symptom relief, not necessarily until an antibiotic course is completed. Antibiotics treat the underlying UTI, while phenazopyridine addresses symptoms. This statement is inaccurate, as their durations are independent, based on clinical need, not synchronized completion.

Choice C reason: Phenazopyridine is not contraindicated in UTIs; it is specifically indicated for symptomatic relief in these infections. It does not treat the infection but alleviates discomfort. This statement is inaccurate, as phenazopyridine is a standard adjunctive therapy in UTI management for pain relief.

Choice D reason: Phenazopyridine provides relief within hours, not almost immediately. Its onset requires absorption and distribution to the urinary tract, typically taking 1-2 hours. This statement is inaccurate, as the relief, while rapid, is not instantaneous, and patients should be informed of the expected timeframe.